Drug intelligence / Profile preview

Cannatol

Development stage: Unknown
Lead developer: Kannalife Sciences
Modality: Small Molecules
Administration: Intranasal, Sublingual

Overview

Cannatol is a high-yield cannabidiol (CBD) compound. It was acquired by KannaLife Sciences from Biotech Inc. as part of a 50/50 joint venture, South Park Ventures (SPV), formed to establish industry standards for cannabis-based phyto-medical products. The collaboration leverages Biotech Inc.'s expertise in producing high-quality organic CBD for KannaLife's standardization processes.

Targets

FAAH

Beyond the preview

Go deeper on Cannatol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cannatol.

Explore the full profile